PharmaTimes - December 2017

With another year almost gone it’s time once again to look back at how the pharma and healthcare industries have fared over the last 12 months.

Despite a lot of upheaval last year, it’s clear that there are still promising times ahead for the industry, even though there will be plenty of hurdles to overcome along the way. You can read in-depth thoughts from some of PharmaTimes’ best writers in our Review of the Year feature on p22 – which includes analysis of the NHS’ transformation over 2017, new government policies, the rise of AI in pharma, and trends in M&A.

But it’s always important to look forwards as well as backwards, and so this issue is also chock full of articles on topics that look likely to become big talking points in 2018 – such as the rise of flexible working in pharma (p16) and how patent litigation might change in an era of personalised medicines (p20). We also take a look at the growing need for more efficiencies in clinical trials on p32.

Finally on p38 we celebrate the winners of this year’s Marketer of the Year competition, and on p40 National Market Access Lead of the Year winner Gawain Shirley gives us his perspective on the UK’s market access landscape.

I hope you enjoy the issue.

December 2017 - magazine highlights

The changing face of post-marketing research

A look at the rise of real-world evidence and humanistic p...

How much do we really understand the patient?

New approaches to studying adherence

Finding pharma’s future

With pharma changing rapidly and Brexit on the horizon, wh...

Loud and clear

We asked the winning companies from the 2017 Communication...

3D printing drugs: more precise, more personalised

Printing out your own medicines is a long way off, but the...

Going Dutch

How pharma regulation could change after the European Medi...

Easing the burden

A guide to best practices in conducting rare disease trial...

Patient Files: Schizophrenia

PharmaTimes talks to Andrew Voyce about his experiences wi...

Rare opportunity

Inside the world of rare diseases with Joe Wiley, CEO of A...

Come together

New NHS care models and CCG mergers require an innovative,...

Beyond ‘beyond the pill’

How pharma companies can take patient-centricity and socia...

Pharma companies fall foul of ABPI’s Code of Practice

Sunovion Pharmaceuticals Europe, Bayer, Astellas UK, Astel...

Patient Files: Rheumatoid arthritis

Philip Aherne  was diagnosed with rheumatoid arthritis at...

Perfect fit

How will patent litigation need to change in an age of bes...

End of the tied-down worker?

Why a more flexible workforce is key to unlocking growth i...

The bigger picture

How to create value with beyond the pill services

Review of the Year: Transition and transformation for the NHS

Paul Midgley and Steve How of Wilmington Healthcare look b...

PharmaTimes Marketer & Communications Team of the Year Awards 2017: Winners announced

The PharmaTimes Marketer & Communications Team of the Year...

Review of the Year: Pharma M&A 
shows its staying power

With macro drivers boosting the sector and  a range of att...

Review of the Year: Empty words?

How will political turmoil affect the government’s 2017 pr...

Review of the Year: Is the UK leading 
the way in AI?

One of the biggest tech trends of 2017 has seen pharma com...

Efficiency drive

Clinical trials are vastly expensive, but innovations are...

Access to success

This year’s winner of the inaugural National Market Access...